RhyGaze raises €77.4M Series A round
13 January 2025· Basel, Switzerland· health, biotech, gene_therapy, b2b, deep_hardware
The funding will be used for the further development of RhyGaze's lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness. Activities to be supported include formal pharmacology and toxicology testing, a non-interventional, observational study to assess potential clinical endpoints in patient groups eligible for the therapy and a first-in-human clinical trial to test the safety, tolerability and potential efficacy of the lead candidate.
Investors
LeadGV
Also participating
Novartis Venture FundF-Prime CapitalBioGeneration VenturesArch Venture Partners
About RhyGaze
Stage
Series A
Headquarters
Basel, Switzerland
Founded
2024
Team Size
1–5
Sectors
healthbiotechgene_therapyb2bdeep_hardware